Research programme: tuberculosis therapies - GPC Biotech

Drug Profile

Research programme: tuberculosis therapies - GPC Biotech

Alternative Names: AX 20017; TBT1 tuberculosis series - GPC Biotech; TBT3 tuberculosis series - GPC Biotech

Latest Information Update: 23 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GPC Biotech AG
  • Class
  • Mechanism of Action Protein kinase G inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 01 Jun 2005 The tuberculosis programme is available for licensing (
  • 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
  • 12 Nov 2004 Preclinical trials in Tuberculosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top